10-K: Perrigo Faces $1.4B Loss, Goodwill Impairments in 2025

Perrigo Company plc reported a substantial net loss of $1.425 billion in 2025, primarily driven by $1.363 billion in goodwill impairment charges, alongside ongoing strategic reviews and operational enhancements.

Summary

• Perrigo reported a net loss of $1,425.4 million in 2025, a significant increase from the $171.8 million net loss in 2024.
• Operating income shifted from a positive $112.9 million in 2024 to an operating loss of $1,122.2 million in 2025.
• Net sales decreased by $120.3 million, or 2.8%, to $4,253.1 million in 2025.
• Goodwill impairment charges totaled $1,325.3 million in 2025, affecting both the Consumer Self-Care Americas (CSCA) with $917.1 million and Consumer Self-Care International (CSCI) with $407.1 million segments.
• The interest rate on the 2030 Senior Notes will increase from 4.900% to 5.150% after June 15, 2026, following a credit rating downgrade by Moody's Investor Services.
• The company completed the sale of the Richard Bittner Business AG for $14.4 million, resulting in a pre-tax loss of $1.6 million.
• Strategic reviews of the infant formula and oral care businesses have been initiated to assess a full range of alternatives.
• A two-year enterprise-wide operational enhancement program was launched, targeting $80 million to $100 million in gross pretax annual run-rate cost savings and a 7% workforce reduction.
• Perrigo is transitioning to a category-based segment reporting structure in Q1 2026, which is expected to result in estimated structural noncash goodwill impairment charges of up to $350 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report, primarily due to the substantial net loss driven by significant goodwill impairments and declining sales, indicating underlying business challenges despite strategic initiatives. The immediate outlook includes further potential impairment charges and workforce reductions, signaling continued instability.

Positives

• The Supply Chain Reinvention Program achieved approximately $157 million in annualized benefits by the end of fiscal year 2025.
• Project Energize achieved approximately $167 million in annualized pre-tax savings by the end of fiscal year 2025.
• Upper Respiratory net sales in CSCA increased by 5.8% to $529.5 million.
• Healthy Lifestyle net sales in CSCA increased by 3.1% to $316.4 million.
• Women's Health net sales in CSCI increased by 8.0% to $143.5 million.
• Digestive Health net sales in CSCI increased by 10.4% to $40.3 million.
• The One Big Beautiful Bill Act (OBBBA) tax law changes resulted in a tax benefit of $21.7 million for 2025.
• The company successfully settled D&O insurance coverage litigation, receiving a $98 million payment in 2024.
• The tax dispute with the IRS regarding Athena Neurosciences, LLC was favorably resolved with an immaterial impact.
• The Canadian Class Action Complaint against Perrigo entities was dismissed with prejudice on February 20, 2026.
• The New Mexico state court ranitidine action against the company was dismissed in March 2025.
• Settlements in principle were reached for Illinois and California state court ranitidine lawsuits, expected to be fully funded by insurance.

Negatives

• Reported a net loss of $1,425.4 million in 2025, a significant increase from the $171.8 million loss in 2024.
• Operating income declined substantially, resulting in a loss of $1,122.2 million in 2025 compared to an income of $112.9 million in 2024.
• Net sales decreased by 2.8% to $4,253.1 million in 2025.
• Incurred $1,325.3 million in goodwill impairment charges in 2025, reflecting a reduction in the estimated fair value of acquired assets.
• The interest rate on the 2030 Senior Notes increased from 4.900% to 5.150% after June 15, 2026, due to a Moody's credit rating downgrade.
• CSCA net sales decreased by 4.0% ($108.4 million), primarily due to lower sales in Digestive Health ($55.4 million), Nutrition ($41.0 million driven by infant formula), and Oral Care.
• The infant formula business was negatively impacted by lost distribution of the Good Start brand and lower contract manufacturing volumes.
• CSCI net sales decreased by 0.7% ($11.9 million), influenced by prior year divestitures and lower sales in Skin Care and VMS.
• Gross profit decreased by $48.2 million, with the gross profit percentage declining by 20 basis points to 35.1%.
• Operating expenses increased by $1,186.9 million, predominantly due to the goodwill impairment charges.
• Net cash from operating activities decreased by $124.4 million.
• Net cash from investing activities decreased by $154.2 million, primarily due to the absence of prior year divestiture proceeds.
• Increased dividend payment by $6.8 million compared to the prior year, reducing available cash.
• No share repurchases were made in 2024 or 2025, and none are anticipated in the near term.
• Ongoing higher compliance costs and reduced production volumes in the infant formula business are expected due to evolving FDA regulatory expectations and remediation actions.
• Operation Stork Speed, a U.S. regulatory initiative, extends the personal importation policy for infant formula, potentially increasing competitive pressures in the U.S. market.
• An estimated structural noncash goodwill impairment charge of up to $350 million is expected in Q1 2026 due to the segment reorganization.
• A new securities class action complaint was filed on November 17, 2025, related to the infant formula business and its strategic review.

Risks

• Intense competition from other consumer packaged goods and pharmaceutical companies, including brand-name and generic manufacturers, could threaten demand and pricing.
• Inability to continuously develop, manufacture, and market innovative products, new line extensions, and expand into adjacent categories could negatively impact net sales and market share.
• Operating in highly regulated industries means any failure to timely meet current or future regulatory requirements (e.g., EU Green Deal, FDA generic drug approvals, nitrosamine impurities, Rx-to-OTC switches, infant formula regulations, medical device regulations) could materially adversely affect business and operating results.
• Limitations on reimbursement, ongoing healthcare reforms, and changes to reimbursement methods in the U.S. and other countries may adversely affect financial condition and operating results.
• Unfavorable publicity or consumer perception regarding the safety, quality, and efficacy of products (e.g., product contamination, counterfeiting, infant formula contamination, negative social media) could damage reputation and reduce demand.
• Lack of availability or significant increases in the cost of raw materials (e.g., due to labor, commodities, tariffs, inflation, API supply from Israel, raw milk for infant formula) could materially affect profit margins and operating results.
• Disruption of the supply chain due to pandemics, global health crises, wars (Ukraine, Middle East), labor shortages, natural disasters, or other civil unrest could materially adversely affect business, financial condition, results of operations, and cash flows.
• A significant disruption at any of the main manufacturing facilities could materially and adversely affect business, financial position, and results of operations.
• Negative performance by collaboration partners and suppliers could materially adversely affect the business.
• Dependence on certain customers for a significant portion of sales (Walmart Inc. represented 12.9% of consolidated net sales in 2025) means disruption of these relationships or adverse changes in customer businesses could have a material impact.
• Deteriorating economic conditions, shifts in the retail landscape, and changes in consumer behavior could adversely affect businesses and lead to volatile results.
• Inability to achieve operating results in line with published guidance could lead to share-price volatility, investor lawsuits, and activist shareholder activity.
• Exposure to cybersecurity threats and third-party information system vulnerabilities could result in a material adverse effect on the business.
• Inability to timely and responsibly leverage emerging technologies, including generative artificial intelligence, or risks associated with their use (cybersecurity, data privacy, intellectual property, algorithmic errors, regulatory action, legal liability, reputational harm) could adversely affect the business.
• Failure to comply with data privacy laws and regulations (e.g., CCPA, UK DPA, GDPR) could result in a material adverse effect on the business.
• Management transition and the ability to attract and retain key personnel create uncertainties that may negatively impact the business.
• Failure to realize the benefits of business acquisitions, divestitures, and other strategic transactions (e.g., earnout payments for Rare Diseases Business, increased costs/reduced volumes from Gateway acquisition) could have a material adverse effect on operating results.
• Significant goodwill and intangible assets on the balance sheet ($2.1 billion and $2.4 billion, respectively, as of December 31, 2025) could become impaired, leading to material charges in the future.
• There is no assurance that the business strategy and related strategic initiatives, including restructurings, will be executed effectively or achieve their intended effects.
• Failure to effectively monitor ESG strategies, initiatives, and risks, or satisfy evolving stakeholder expectations (e.g., EU Corporate Sustainability Reporting Directive, Corporate Sustainability Due Diligence Directive) may negatively affect business and operations.
• Inability to maintain effective internal control over financial reporting could adversely affect investor confidence and share price.
• Risks arising from the international scope of operations, including changes in regulatory requirements, new/additional tariffs (e.g., U.S. government tariffs, potential pharmaceutical tariffs), trade policies, political tensions, and economic/geopolitical instability (Ukraine, Middle East).
• Exposure to risks associated with foreign exchange rates (Euro, British pound, Canadian dollar, Swedish Krona, Chinese Yuan, Danish Krone, Polish Zloty).
• Involvement in numerous lawsuits (product liability, patent, commercial, regulatory, antitrust, securities litigation, talcum powder, ranitidine, acetaminophen, phenylephrine, PLD & Conry litigation) could result in significant monetary damages and legal expenses.
• Increased scrutiny on pricing practices and competition, including antitrust enforcement activity and class action litigation, may have a material adverse impact on business and operating results.
• Third-party patents and other intellectual property rights may limit the ability to bring new products to market and subject the company to potential legal liability.
• Failure to adequately protect intellectual property rights and patents could allow competitors to manufacture and market similar products.
• Significant increases in the cost or decreases in the availability of insurance, or disputes with insurers on policy scope, could adversely impact operating results and financial condition.
• Unfavorable resolution of uncertain tax positions or ongoing disputes with U.S. and foreign tax authorities (e.g., IRS audits related to transfer pricing, omeprazole sales, ANDA legal expenses) could have a material adverse effect.
• Changes to tax laws and regulations or their interpretation (e.g., Section 7874 of the Code, OECD Pillar Two) could materially adversely affect results of operations and ability to utilize cash efficiently.
• Changes in the effective tax rate or cash tax payment requirements in the future could adversely impact future results of operations.
• Indebtedness of $3.6 billion at December 31, 2025, could adversely affect the ability to invest in the business and implement strategic initiatives, with credit agreements imposing material operating and financial restrictions.
• There is no guarantee that the company will buy back ordinary shares pursuant to its announced plan or that such a plan would enhance long-term shareholder value.
• Any additional shares issued could dilute existing ownership in the company.
• Incorporation in Ireland means Irish law differs from U.S. law and may afford less protection to, or otherwise adversely affect, shareholders.
• The ability to pay dividends in the future may be limited by factors such as distributable reserves, debt covenants, and financial condition.

Future Outlook

Perrigo expects to regularly propose the renewal of authorization for its board of directors to issue up to approximately 20% of its issued share capital at annual general meetings. The company anticipates less than $10 million in additional costs for the wind-down activities of both the Supply Chain Reinvention Program and Project Energize through fiscal year 2026. Higher compliance costs are expected to continue for the infant formula business. The operational enhancement program is projected to achieve gross pretax annual run-rate cost savings of $80 million to $100 million, mostly in 2026, with associated cash costs ranging from $80 million to $90 million. Capital expenditures for 2026 are anticipated to be between $90 million and $130 million. While the company expects to continue paying cash dividends, there is no assurance regarding future amounts or declarations, and no share repurchases are anticipated in the near term. An estimated structural noncash goodwill impairment charge of up to $350 million is expected in Q1 2026 due to the segment reorganization. Irish regulators are expected to issue a final opinion in 2026 on the reclassification of codeine to prescription-only status.

Management Comments

• Our vision is 'To Provide The Best Self-Care For Everyone' and our purpose is to 'Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All'.
• Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.
• The Company's plan to drive cash flow and total shareholder return is anchored behind its Three-S plan – Stabilizing Consumer Self-Care Americas store brand and infant formula businesses; Streamlining the global portfolio, enterprise operating model and Consumer Self-Care International business; and Strengthening what is working by prioritizing and increasing investments behind key brands.
• Although we believe these leadership transitions are in the best interest of our stakeholders, any change in executive management creates uncertainty.
• We intend to vigorously defend against any lawsuits, however, we cannot predict how the cases will be resolved.
• We believe that our existing global tax strategies will adequately address any necessary adjustments to comply with Pillar Two without significantly affecting our effective tax rate or overall financial position.
• We are not anticipating the remaining provisions of the OBBBA to have a material effect on our consolidated financial statements.
• Based on the foregoing, management believes that our operations and borrowing resources are sufficient to provide for our short-term and long-term capital requirements.
• We continue to monitor the progress of our reporting units and assess them for potential impairment should impairment indicators arise, as applicable, and at least annually during our fourth quarter impairment testing.

Industry Context

StockSavvy.ai notes that Perrigo operates in a highly competitive self-care market, facing pressure from both national brands and other private label manufacturers. The company's strategic focus on 'pure-play self-care' and its 'Three-S plan' (Stabilize, Streamline, Strengthen) reflects a broader industry trend towards portfolio optimization and efficiency in the consumer health sector. The ongoing regulatory scrutiny in the infant formula market and the evolving landscape for OTC products like phenylephrine and ranitidine highlight the significant regulatory risks inherent in the pharmaceutical and consumer health industries. Geopolitical events and global supply chain disruptions continue to impact material sourcing and costs across the industry, necessitating adaptive strategies like those Perrigo is implementing.

Comparison to Industry Standards

• Perrigo's gross profit percentage of 35.1% in 2025 is generally comparable to other diversified consumer health companies, though specific product categories and business models (e.g., private label vs. pure brand) can lead to variations. For instance, companies like Haleon or Kenvue, with stronger brand portfolios, might target higher gross margins.
• The significant operating loss and net loss, driven by substantial goodwill impairments, are substantially worse than industry averages for healthy, growing consumer health companies, which typically aim for consistent profitability and asset value stability.
• The credit rating downgrade by Moody's to Ba3 from Ba2 indicates a weaker credit profile compared to many investment-grade peers in the consumer health sector, potentially increasing borrowing costs and limiting financial flexibility. Companies like Johnson & Johnson or Procter & Gamble typically maintain much higher credit ratings.
• The numerous ongoing legal challenges related to drug pricing (antitrust), talcum powder, ranitidine, and acetaminophen are common across the pharmaceutical and consumer goods industries, with many large players like Johnson & Johnson, GSK, and Bayer facing similar litigation. The scale and number of Perrigo's cases, however, represent a significant ongoing burden.
• The strategic reviews of the infant formula and oral care businesses, along with the operational enhancement program, suggest a need for significant restructuring and efficiency gains, which is a common theme in mature consumer goods industries but indicates underperformance in certain segments relative to market leaders.

Management Changes

Corporate Governance

Legal Proceedings

• **Price-Fixing Lawsuits (Former Rx Business)**: The company is a defendant in 45 pending lawsuits in the MDL court and other state/federal courts, plus 5 new complaints in 2025, alleging anticompetitive conduct for generic drugs. The Humana bellwether case trial is scheduled for September 15, 2026, and Kroger and Cigna bellwether trials are set for August 2027 and January 2028, respectively. The Connecticut Attorney General lawsuit (50 states/territories) is remanded to the District of Connecticut, with summary judgment briefing complete. The Canadian class action complaint against Perrigo entities was dismissed with prejudice on February 20, 2026.
• **Securities Litigation (2015-2017 events)**: The U.S. class action (Roofer's Pension Fund v. Papa, et al.) settled for $97.0 million in April 2024, with final approval granted on September 5, 2024. Individual opt-out cases settled in 2024 or 2025, resulting in an additional loss provision of $28.9 million in 2025. The Israeli class action was dismissed in 2018 and not revived.
• **Securities Litigation (2023-2025 events)**: A new purported securities class action complaint was filed on November 17, 2025 (Tanner French v. Perrigo Company plc, et al.) alleging violations related to the infant formula business and its strategic review. A lead plaintiff was appointed on February 13, 2026.
• **Talcum Powder Lawsuits**: Approximately 290 individual lawsuits are pending, alleging mesothelioma and lung cancer due to asbestos contamination in legacy talcum powder products. Over 41 trials are scheduled for 2026 and 2027. Retailer customers are seeking indemnity.
• **Ranitidine Litigation**: The MDL (In re Zantac/Ranitidine Products Liability Litigation) dismissed all claims against Perrigo with prejudice on July 8, 2021, based on federal preemption and scientific causation. Appeals to the 11th Circuit were filed, with oral arguments held on October 10, 2025. Illinois state court lawsuits settled in principle in April 2025 for an immaterial amount, expected to be fully funded by insurance. California state court lawsuits settled in principle in November 2024 for an immaterial amount, expected to be fully funded by insurance. A New Mexico state court action was dismissed in March 2025. There are no active lawsuits against the company at the trial court level.
• **Acetaminophen Litigation**: The MDL (In re: Acetaminophen ASD/ADHD Products Liability Litigation) consolidated actions alleging prenatal exposure linked to ASD/ADHD. The MDL court granted defendants' motions to exclude causation expert testimony in December 2023 and July 2024. Final judgment was entered, and appeals to the Second Circuit are fully briefed, with argument held on November 17, 2025. Perrigo is not named as a defendant, but customers are seeking indemnity.
• **Phenylephrine Litigation**: The MDL (In re: Oral Phenylephrine Marketing and Sales Practices Litigation) consolidated actions challenging efficacy. The court dismissed the bellwether complaint in October 2024 based on federal preemption and lack of standing for RICO claims. An appeal to the Second Circuit was filed, with oral argument set for March 4, 2026. Retailer customers are seeking indemnity.
• **PLD & Conry Litigation**: Perrigo is a defendant in two pending litigations alleging anticompetitive conduct related to infant formula supply and the acquisition of the Gateway facility. Motions to dismiss are pending, discovery is ongoing, and initial expert disclosures are expected in June 2026.
• **IRS Audits**: Ongoing tax disputes with the IRS related to transfer pricing (omeprazole sales) and ANDA-related adjustments for fiscal years 2009-2012, 2013-2015, and 2015-2019. A court opinion in the U.S. tax refund case (2009-2012) predominantly sided with Perrigo U.S. on September 25, 2025, with a final judgment issued on January 27, 2026.

Stakeholder Impact

• **Shareholders**: Experienced a significant net loss and goodwill impairment, negatively impacting shareholder value. No share repurchases are anticipated in the near term, and potential future share issuance could lead to dilution. Irish law differences may afford less protection compared to U.S. law.
• **Employees**: The operational enhancement program is expected to reduce approximately 7% of the current workforce, leading to job losses. Management changes create uncertainty for personnel. The company emphasizes fostering a culture of inclusivity and teamwork, and provides well-being programs.
• **Customers**: Supply chain disruptions, increased costs due to tariffs, and regulatory issues could impact product availability and pricing. The company's dependence on certain large customers (e.g., Walmart Inc. for 12.9% of net sales) creates concentration risk.
• **Creditors**: The company has $3.6 billion in indebtedness, and a recent credit rating downgrade by Moody's could increase future borrowing costs. Financial covenants in debt agreements impose restrictions on operations.
• **Consumers**: Affected by product recalls, potential contamination, and efficacy concerns related to certain products (e.g., ranitidine, phenylephrine). The company aims to provide high-quality, affordable, and accessible self-care solutions.

Next Steps

• Propose renewal of authorization to issue up to 20% of share capital at annual general meetings.
• Finalize Supply Chain Reinvention Program and Project Energize wind-down activities through fiscal year 2026, with anticipated additional costs of less than $10 million for each program.
• Continue to monitor and adjust processes for infant formula to remain in compliance with evolving FDA regulations.
• Continue to mitigate tariff impacts through strategic pricing, insourcing, and supply chain actions.
• Continue to monitor conflicts in Ukraine and the Middle East for impacts on operations and supply chain.
• Implement the two-year enterprise-wide operational enhancement program, including a 7% workforce reduction and operational cost reductions, with the majority of $80 million to $100 million gross pretax annual run-rate cost savings expected in 2026.
• Conduct strategic review of infant formula and oral care businesses.
• Transition from geographic to category-based segment reporting structure in Q1 2026.
• Recognize estimated structural noncash goodwill impairment charges of up to $350 million in Q1 2026 due to segment reorganization.
• Irish regulators expect a final opinion in 2026 on the reclassification of codeine to prescription-only status.
• Over 41 trials for talcum powder lawsuits are scheduled throughout 2026 and 2027.
• Expert discovery in the Humana bellwether case closes February 27, 2026; summary judgment briefing begins March 6, 2026, and is completed by April 20, 2026; trial scheduled for September 15, 2026.
• Trials for the Kroger and Cigna bellwether cases are set for August 2027 and January 2028, respectively.
• Oral argument is set for the phenylephrine appeals on March 4, 2026.
• Initial expert disclosures for the PLD & Conry litigation are expected in June 2026.
• Anticipated 2026 capital expenditures are between $90 million and $130 million.
• Continue to vigorously defend against ongoing lawsuits.

Key Dates

Recommendation

Perrigo's 2025 results show a substantial net loss driven by significant goodwill impairments, indicating a fundamental revaluation of its assets and future prospects. Declining sales, ongoing regulatory challenges in key segments like infant formula, and a credit rating downgrade suggest persistent operational and financial headwinds. While restructuring efforts are underway, the immediate outlook includes further potential impairment charges and workforce reductions, signaling continued instability. The numerous ongoing litigations also present significant unquantifiable risks. These factors collectively point to a challenging environment for the company, making it a 'sell' for a seasoned investor.

Keywords

Perrigo, self-care, OTC, pharmaceuticals, consumer health, infant formula, goodwill impairment, debt, SEC filing, 10-K, financial results, strategic review, supply chain, regulatory compliance, litigation, Ireland, US